The global pulsed field ablation market size is expected to be worth USD 148.9 Million in 2025. It can balloon to a valuation of USD 1,593.3 Million by 2032. The market is anticipated to exhibit a CAGR of 40.3% during the forecast period (2025-2032).
The rise in cardiovascular diseases and the breakthroughs in minimally invasive surgeries are factors expected to drive the market growth over the forecast period. Advances in pulsed field ablation (PFA) systems and initiatives by doctors and medical institutions for enlightening patients facilitated the market penetration.
However, the high costs of PFA devices and the risks of strokes on their use can impede the market growth.
Key Market Insights
The pulsed field ablation market is anticipated to surge owing to advances in catheter designs, integration of real-time imaging technologies, and incorporation of AI-driven technologies.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/pulsed-field-ablation-market
Pulsed Field Ablation Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 148.9 Million |
|
Estimated Value by 2032 |
USD 1,593.3 Million |
|
Growth Rate |
40.3% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Components, Indication, and End User |
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The effective treatment of atrial fibrillation using PFA systems has transformed the pulsed field ablation market. Advances in catheters have taken strides in the efficacy and safety of patients, which has led to the approval of 3 PFA systems by the U.S. Food & Drug Administration in 2024. This is demonstrated by Kardium Inc.'s PULSAR Investigational Device Exemption (IDE) study, which evaluates the safety and efficacy of its Globe Pulsed Field System. The study conducted on paroxysmal atrial fibrillation patients witnessed a 78% success rate as patients treated were free of the disorder after a year.
The pairing of real-time imaging systems with PFA systems can bode favorably for the market. Leading medical device manufacturers like Abbott have been working on overcoming the limitations of three-dimensional visualization and the mapping of the affected area. This can help the device be more precise with the treatment and ablate areas causing arrhythmia.
Market Opportunity: Preference of PFA over Thermal Ablation
The advantage over thermal ablation techniques owing to its ease of use and efficacy can create a prime opportunity for the pulsed field ablation market over the forecast period. The selective mechanism of PFA makes it easier to target selected tissues, while thermal ablation requires extensive operator experience for safety of the patient.
The shorter recovery procedures on the use of PFA, as well as the fast regulatory approvals of the systems can boost the pulsed field ablation market growth significantly. On April 07, 2025, the Volt pulsed field ablation system gained approval for sale in the European Union. The product was deemed effective for pulmonary vein isolation in patients with atrial fibrillation.
Market Challenge: Recall of PFA Systems a Major Setback
The product recall of ablation catheters by regulatory authorities can be a real setback to the market growth. On February 28, 2025, the U.S. Food & Drug Administration ordered a recall of Johnson & Johnson’s ablation catheters that are a part of its PFA system. The warning was sounded after 3% of patients in the U.S. died from a stroke after their treatment using the system.
Analyst’s View
Recent Developments
Field Medical, a U.S. medical technology-centered startup, raised USD 35 Million on July 02, 2025, for the development of its PFA system. The system is designed to treat ventricular tachycardia, a heart rhythm disorder.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :